Iopidine (Apraclonidine)

Apraclonidine selectively stimulates alpha‑2 adrenergic receptors in the eye, which reduces aqueous humor production and enhances uveoscleral outflow, leading to a decrease in intraocular pressure. This dual action helps control pressure spikes associated with glaucoma and postoperative periods.

The dosing regimen for Iopidine is determined by the prescribing ophthalmologist based on the individual’s condition, severity, and response. Typically, one drop is instilled in the affected eye(s) once or twice daily, but the exact schedule should follow the prescriber’s instructions.

The safety of apraclonidine in pregnancy and lactation has not been established; it is classified as pregnancy category unknown. Use is only recommended if the potential benefit justifies the potential risk, and it should be avoided unless specifically advised by a qualified healthcare provider.

To place an order, submit an enquiry on the Iopidine product page at gnhindia.com, providing the required quantity and your institutional credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional verification before supplying pricing, availability, shipping details and necessary import documentation.

Compared with beta‑blocker eye drops, apraclonidine offers a different mechanism by targeting alpha‑2 receptors, which can be useful as adjunct therapy or when beta‑blockers are contraindicated. It may have a milder systemic profile but can cause ocular irritation more frequently than prostaglandin analogues.

Store Iopidine at room temperature, below 25 °C, in the original container. Keep the bottle tightly closed, protect it from light and moisture, and avoid freezing. Do not use the product after the expiration date printed on the label.

Iopidine is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and instill one drop into the conjunctival sac of the affected eye(s). Close the eye gently for a few seconds and avoid blinking excessively.

Although uncommon, serious adverse reactions can include severe ocular inflammation, corneal edema, and systemic hypotension or bradycardia, especially when used with other systemic antihypertensives. Prompt medical attention is required if these symptoms occur.

Iopidine should be avoided in patients with known hypersensitivity to apraclonidine or any component of the formulation, and in those with severe ocular inflammation or infection. Caution is also advised for individuals with cardiovascular disease or those taking systemic alpha‑2 agonists.